A recent study in ET patients has shown that JAK2-V617F mutations cause increased systemic inflammatory levels,33 but high-sensitivity C-reactive protein (hsCRP) levels were not significantly increased in thrombocytosis cases carrying a JAK2-V617F mutation compared with those without a JAK2-V617F mutation in our population-based cohort (P = 0.083). The gene discussed is JAK2; the disease is essential thrombocythemia.